A recent study from the Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, New York, USA has reported that excess of central TGF-β induces hyperglycemia and glucose intolerance. This study was published in the August 3 2014 Nature Medicine (The number 1 journal in Medicine) by Prof Cai D, Yan J, and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Therapeutic insights into the treatment of Aging- and Weight gain-induced T2D: MiRNA-101 inhibits hyperglycemia and glucose intolerance via down regulation of its target gene. This study suggests that miR-101, by decreasing the expression of its target gene, it may inhibit hyperglycemia and glucose intolerance. Together, this study suggests that pharmacological formulations encompassing “miR-101 activators” may be used to treat aging- and weight gain-induced hyperglycemia, -glucose intolerance and -T2D.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Therapeutic insights into the treatment of Aging- and weight-gain-induced T2D: MiRNA-101 inhibits hyperglycemia and glucose intolerance via down regulation of its target gene, 8/August/2014, 9.33 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation